$LUCD

Lucid Diagnostics reported Q2 2026 revenue of $1.5M, up 17% from the prior quarter. The company performed 2,770 EsoGuard tests, within its target range. Cash reserves remained at $33.4M, with $16.8M raised from a stock offering. GAAP net loss was $14.7M, or $0.08 per share. Management highlighted progress in commercial coverage and Medicare reimbursement efforts, noting a shift to higher-probability revenue sources. The company also secured $22M in convertible debt and reported a 65% claim adjud

Lucid Diagnostics (LUCD) confirmed its first LBM win with Concert, which covers 10M lives. Analyst Mark Massaro maintained a Buy rating and $2.50 price target, citing strong clinical evidence for its EsoGuard test. Q2 revenue grew 27% YoY to $1.5M, with a loss of 8 cents per share. The company awaits CMS coverage for EsoGuard, with management expressing confidence in a positive draft LCD.

PAVmed Inc. (NASDAQ: PAVM) reported Q2 2026 results for the quarter ended June 30, 2026 and provided business updates across subsidiaries Lucid Diagnostics (NASDAQ: LUCD), Veris Health, and Octeris. Lucid recognized $1.5M EsoGuard revenue and processed 2,770 tests, and secured first lab benefit manager coverage. PAVmed cash was $3.8M; GAAP net loss was $5.5M ($0.87/share).

Simply Wall St reports Lucid Diagnostics (LUCD) shares fell about 2%. The article cites Q2 2026 revenue of about $1.5M, up from $1.163M, but continued net losses and negative EPS. It highlights a high price-to-sales multiple (35.9x), test volume of 2,770 EsoGuard tests, cash of $33.4M, and ongoing reimbursement and adoption concerns.

Needham reiterated a Buy rating on Lucid Diagnostics Inc (NASDAQ:LUCD) and set a $3.00 price target, versus about $0.97. The article cites Q2 2026 EsoGuard test volume up 1% to 2,770, revenue of $1.47M vs $1.43M consensus, and a 6-cent-per-share loss. It notes about $33M cash and continued negative free cash flow.

Lucid Diagnostics (NASDAQ: LUCD) reported Q2 2026 revenue of $1.5 million, up 17% QoQ, driven by 2,770 EsoGuard tests. The company said Concert issued its first Laboratory Benefit Manager coverage policy for EsoGuard. Cash was $33.4 million at June 30, with $11.3 million quarterly burn. It awaits a Medicare draft LCD and is progressing with VA.

Lucid Diagnostics reported Q2 2026 revenue of $1.47 million, up 17% sequentially and above the $1.43 million estimate, driven by more EsoGuard insurance claims recognized. EPS was a loss of 6 cents, matching forecasts. The company performed 2,770 EsoGuard tests and reiterated Medicare coverage as the key near-term catalyst; shares fell slightly in premarket.

Lucid Diagnostics Inc. (LUCD) reported Q2 adjusted EPS loss of $0.06 per share, wider than the Zacks Consensus Estimate of a $0.04 loss. Revenue was $1.47M for the quarter ended June 2026, missing consensus by 1.73% and up from $1.16M a year earlier. The article cites a Zacks Rank #3 (Hold) and upcoming consensus EPS of -$0.04 on $2M revenue for the next quarter.

Lucid Diagnostics (NASDAQ: LUCD) reported Q2 EPS of -$0.0600, matching the analyst estimate, and revenue of $1.47M, above the $1.43M consensus. The stock closed at $0.98. The article notes recent EPS revisions and a “weak performance” financial health score from InvestingPro.

Lucid Diagnostics Inc. (LUCD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results Recognized 2Q26 revenue of $1.5 million Processed 2,770 EsoGuard ® tests Secured first laboratory benefit manager (LBM) EsoGuard coverage policy Conference call and webcast t